Omega Therapeutics Inc

NASDAQ:OMGA  
3.74
+0.12 (+3.32%)
4:00:11 PM EDT: $4.38 +0.64 (+17.11%)
Products, Regulatory

Omega Therapeutics Submits IND Application For OTX-2002 For MYC Driven Hepatocellular Carcinoma

Published: 06/15/2022 11:25 GMT
Omega Therapeutics Inc (OMGA) - Omega Therapeutics Announces Submission of Investigational New Drug Application for Otx-2002, an Omega Epigenomic Controller, for Myc Driven Hepatocellular Carcinoma.
Omega Therapeutics Inc -.
Omega Therapeutics Inc - Plans to Initiate a Phase 1 Clinical Trial in U.S. to Evaluate Otx-2002, Following FDA Clearance.